Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)

A Double-Blind, Multicenter, Placebo and Active-Controlled, Acute Extension Study of 2 Doses of MK-0869 in the Treatment of Patients With Major Depressive Disorder

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00048607

Enrollment

600

Registered

2002-11-05

Start date

2002-07-30

Completion date

2003-12-31

Last updated

2017-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Brief summary

A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression

Detailed description

The duration of treatment is 8 weeks.

Interventions

DRUGaprepitant

DRUGComparator: paroxetine HCL

DRUGComparator: Placebo (Unspecified)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients with Major Depressive Disorder

Design outcomes

Primary

Measure	Time frame
HAMD-17 total score at week 8. Tolerability.	at week 8

Secondary

Measure	Time frame
CGI-I Scale score at week 8 and Sheehan Disability Scale at week 8	at week 8

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026